[CIS PIDD] [cis-pidd] NLH and rituximab = NHL

Tue May 26 13:27:23 EDT 2015

She suspect she meant NHL, non-hodgkins lymphoma.  It is remarkable they would deny Rituximab if the NHL is CD20+.

-----Original Message-----
From: Church, Joseph [mailto:JChurch at chla.usc.edu]
Sent: Tuesday, May 26, 2015 9:58 AM
To: CIS-PIDD
Subject: RE:[cis-pidd] NLH and rituximab

Sorry Kate, but what is NLH?
Joe Church

-----Original Message-----
From: Sullivan, Kathleen [mailto:SULLIVANK at email.chop.edu]
Sent: Tuesday, May 26, 2015 7:09 AM
To: CIS-PIDD
Subject: [cis-pidd] NLH and rituximab

I have a CVID patient who has been denied rituximab for NLH by her insurance company for lack of data.  It is true that there are no published studies.  I think they will accept “collective knowledge”.

If you have treated a patient with CVID and NLH with rituximab successfully, would you be so kind as to weigh in on this list serve so I can compile the information and present it to the insurance company?

If others have faced this- perhaps we could channel these data into a short report so it is out there for others to use.

Kate
Kate Sullivan, MD PhD
Wallace Chair
Chief of Allergy Immunology
ARC 1216 CHOP
3615 Civic Center Blvd.
Philadelphia, PA 19104
(p) 215-590-1697
(f) 267-426-0363

---
You are currently subscribed to cis-pidd as: jchurch at chla.usc.edu.
To unsubscribe click here: http://cts.dundee.net/u?id=96396658.df9245d5219d19fc82ac9f3bbf52c836&n=T&l=cis-pidd&o=2860904
or send a blank email to leave-2860904-96396658.df9245d5219d19fc82ac9f3bbf52c836 at lyris.dundee.net

---------------------------------------------------------------------
CONFIDENTIALITY NOTICE: This e-mail message, including any attachments,
is for the sole use of the intended recipient(s) and may contain confidential
or legally privileged information. Any unauthorized review, use, disclosure
or distribution is prohibited. If you are not the intended recipient, please
contact the sender by reply e-mail and destroy all copies of this original message.

---------------------------------------------------------------------

---
You are currently subscribed to cis-pidd as: asaxon at mednet.ucla.edu.
To unsubscribe click here: http://cts.dundee.net/u?id=96396407.796a171b5229f2fd82173d332612cc52&n=T&l=cis-pidd&o=2861357
or send a blank email to leave-2861357-96396407.796a171b5229f2fd82173d332612cc52 at lyris.dundee.net

________________________________

IMPORTANT WARNING: This email (and any attachments) is only intended for the use of the person or entity to which it is addressed, and may contain information that is privileged and confidential. You, the recipient, are obligated to maintain it in a safe, secure and confidential manner. Unauthorized redisclosure or failure to maintain confidentiality may subject you to federal and state penalties. If you are not the intended recipient, please immediately notify us by return email, and delete this message from your computer.

---
You are currently subscribed to cis-pidd as: pagid at list.clinimmsoc.org.
To unsubscribe click here: http://cts.dundee.net/u?id=96396833.5a9591ccd1e327fe6bc4d1543298c482&n=T&l=cis-pidd&o=2861438
or send a blank email to leave-2861438-96396833.5a9591ccd1e327fe6bc4d1543298c482 at lyris.dundee.net